DXVX
Daily close in US$ at the latest USD/KRW close. Source: KRX via FinanceDataReader.
DXVX is a South Korean biotech and healthcare company listed on KOSDAQ that provides genetic diagnostic testing, in-vitro diagnostic kits, and health-supplement products, while also developing novel drugs.
Hospitals, pharmaceutical companies, and research institutions use its genomic testing services, diagnostic reagents, and contract diagnostic manufacturing. Its business spans three distinct segments, medical diagnostics, healthcare products, and drug development, built partly through acquisitions of a health-supplement manufacturer and a drug-pipeline company.
Summary is AI-generated and may contain errors · figures from DART filings
DXVX has established a China-based subsidiary, Beijing DIWays Biotechnology Co., Ltd., to expand its health-supplement exports into the Chinese market.
DXVX in five facts
What does DXVX do?
DXVX is a South Korean biotech and healthcare company listed on KOSDAQ that provides genetic diagnostic testing, in-vitro diagnostic kits, and health-supplement products, while also developing novel drugs.
Where is DXVX listed and in which sector?
DXVX (Korean name: DXVX) trades under KRX code 180400 on KOSDAQ, the Korea Exchange's board for smaller and growth companies. It is classified in the Industrials sector, Commercial Services.
How large is DXVX?
Its market capitalisation was US$152.3M on 2026-10-21, which puts it in this site's small-cap group. US$ amounts are converted from won at 1 USD ≈ ₩1,325 (2026-10-21).
What were DXVX's latest annual revenue and operating profit?
For fiscal year 2025, DXVX reported revenue of US$22.2M, an operating loss of US$18.4M and a net loss of US$22.3M, per its annual report on DART (data retrieved from DART on 2026-09-17). Revenue was down 13.5% on the previous year.
Where does this data come from?
Financial statements and filings come from DART, Korea's official corporate-filing system. Share prices, market capitalisation and trading status come from KRX. Company summaries are AI-generated from the filings and may contain errors; financial figures are mapped directly from DART.
Data sources and last updated
- Filings and financial statements
- DART (dart.fss.or.kr), Korea's official corporate-filing system
- Prices, market cap, trading status
- KRX (Korea Exchange), via FinanceDataReader
- Latest annual financials
- Fiscal year 2025, data retrieved from DART on 2026-09-17
- Share price and market cap
- Close of 2026-10-21
- Currency
- US$, converted from won at 1 USD ≈ ₩1,325 (2026-10-21 close)
- Company data updated
- 2026-10-21
- Company summary
- AI-generated from filings; may contain errors. Information only, not investment advice.
- Report on large shareholdings (5% rule) (standard)Oct 12
- Change of CEOOct 8
- Results of extraordinary shareholders' meetingOct 8
- Report on securities held by executives/major shareholdersOct 1
- Report on large shareholdings (5% rule) (standard)Sep 28
- Proxy solicitation reference documentSep 18
- Notice of general shareholders' meetingSep 18
- Decision to guarantee a third party's debtSep 17
- Change of CEOSep 17
- [Amended] Supply contract signed
DXVX updated a previously disclosed supply contract with Hangzhou Guangsheng Enterprise Management Consulting Co., Ltd., now worth US$7.43M, about 22.11% of its recent annual revenue, running through Aug 2027.
Supply contract · Aug 21 - [Amended] Supply contract signed
DXVX updated a previously disclosed supply contract with OFMEIGHT TRADING CO.,LTD, now worth US$3.65M, about 12.01% of its recent annual revenue, running through Jun 2028.
Supply contract · Jun 19 - Change of 30% or more in revenue or profit/loss structure (15% for large companies)
DXVX reported consolidated results for FY2025: revenue of US$20.2M (−13.15% year on year), an operating loss of US$12.5M and a net loss of US$15.9M.
Earnings · Feb 9